This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human ENPP-2 / Autotaxin Protein, His Tag (active enzyme)
catalog :
EN2-H5241
quantity :
250 ug, 50 ug
price :
580 USD, 290 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
EN2-H5241
product name :
Human ENPP-2 / Autotaxin Protein, His Tag (active enzyme)
quantity :
250 ug, 50 ug
price :
580 USD, 290 USD
quantity & price :
$290/50ug,$580/250ug
target :
ENPP-2
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human ENPP-2, His Tag (EN2-H5241) is expressed from human 293 cells (HEK293). It contains AA Asp 49 - Ile 863 (Accession # NP_001035181).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human ENPP-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH 7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Autotaxin also known as ectonucleotide pyrophosphatase / phosphodiesterase family member 2 (E-NPP 2 or ENPP2), Extracellular lysophospholipase D (LysoPLD), Autotaxin (ATX or ATX-X), which belongs to the nucleotide pyrophosphatase / phosphodiesterase family. ENPP2 contains two SMB (somatomedin-B) domains. ENPP2 hydrolyzes lysophospholipids to produce lysophosphatidic acid (LPA) in extracellular fluids. ENPP2 can act on sphingosylphosphphorylcholine producing sphingosine-1-phosphate, a modulator of cell motility. ENPP2 stimulates migration of melanoma cells, probably via a pertussis toxin-sensitive G protein.
References :
(1) Stracke M.L., et al., 1992, J. Biol. Chem. 267:2524-2529.
(2) Nam S.W., et al., 2001, Cancer Res. 61:6938-6944.
(3) Hausmann J., et al., 2011, Nat. Struct. Mol. Biol. 18:198-204.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments